Skip to main content

Applera and Roche Settle Litigation, Expand Licensing Program for PCR and Real-time PCR

NEW YORK, May 9 (GenomeWeb News) - Applera and Roche Diagnostics have settled their litigation over PCR technology and have included real-time PCR in their PCR licensing program, the companies said today.


The firms have settled their litigation and arbitration about contractual relationships that involved rights to and commercialization of PCR and real-time PCR under undisclosed financial terms.


The companies' licensing program will now include patents for real-time PCR "and other important PCR-related technology," according company statements. Applera's ABI group will be the sole licensor of Roche patents covering methods and reagents for PCR and real-time PCR for life science research and other applications.


Applera has also obtained a diagnostics license, with no right to sublicense, of Roche's nucleic acid technology patents.


In addition, Roche and Applera have granted each other licenses related to PCR technology for research and diagnostics. This includes the right for Roche to manufacture real-time PCR instruments for a third party under certain conditions.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.